A carregar...
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
Pacritinib, potent inhibitor of Janus kinase 2 (JAK2), JAK2V617F, and fms-like receptor tyrosine kinase 3, is in Phase III development in myelofibrosis. Among type 1 inhibitors, pacritinib shows a lack of myelosuppression at doses that both inhibit JAK2/signal transducer and activator of transcripti...
Na minha lista:
| Publicado no: | J Exp Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4993559/ https://ncbi.nlm.nih.gov/pubmed/27574472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S110702 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|